Sunitinib Malate CAS:341031-54-7

Sunitinib malate CAS:341031-54-7 is the orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells. Sunitinib malate CAS:341031-54-7 is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications. Sunitinib malate CAS:341031-54-7 could be supplied in different size with competitive price.
Chat Now

Product Details

--2_01.png

Product Description

Name

High quality Sunitinib malate CAS 341031-54-7

Other name

N-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide (2S)-hydroxybutanedioat(2S)-2-Hydroxysuccinic acid - N-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1,2-dihydro-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide ; Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide

CAS

341031-54-7

Applications

API intermediates

Appearance

Orange-yellow powder

Sunitinib malate CAS:341031-54-7 is the orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells. Sunitinib malate CAS:341031-54-7 is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications. Sunitinib malate CAS:341031-54-7 could be supplied in different size with competitive price.

.jpg

Application

--2_04.png 

Related products
Main product
Company Information

--2_07.png--2_08.png--2_09.png--2_10.png--2_11.png

Packaging & Shipping

--2_12.png 

FAQ

Q1: Can I get some samples?
A: Yes, It is no problem.If you need sample ,please contact with us.
Q2: How to confirm the Product Quality before placing orders?
A:Firstly,we will send the sample for your testing and also provide our testing result.
Secondly,we could accept the third-party inspection.
Q3:What's your MOQ?
A:Normally,our MOQ is 1kg. But it could be according to your actual demandAny quantity is OK.
Q4: How about delivery time?
A:within 3-5 days after payment confirmed. (Chinese holiday not included)
Q5:Is there a discount?
A:Different quantity has different discount.
Q6: How do you treat quality complaint?
A:First of all, our quality control will ensure our quality in advance. If there is a real quality problem caused by us, we will provide good product again or refund your loss.--2_15.png


Hot Tags: sunitinib malate cas:341031-54-7, China, suppliers, manufacturers, factory, wholesale, bulk

Inquiry

You Might Also Like